CM Workshop Workshop Summary Beliefs Form Beliefs Dashboard Cost Model The Unjournal · Pivotal Questions

At a glance

Five questions account for much of the disagreement; each card is a direct link

Here, a crux is not just a general uncertainty. It is a question whose answer would materially change the cost forecast or the chance that the forecasted industry exists.

How to comment or respond

Three options, depending on how much you want to say
Respond to a cruxUse the short form below. You can submit publicly under your name, publicly but anonymously, or privately to The Unjournal.
Give a full numerical forecastUse the beliefs form for p10/median/p90 estimates and the technical subquestions.
Comment on a passageUse the Hypothes.is sidebar on the right edge for a public annotation attached to exact text.

Scope and representation

Why this should not be read as a field-wide consensus map
The workshop participant group was largely drawn from people already working in or closely adjacent to the CM field, and as Bert Frohlich noted in S3, "we are kind of the believers." The map therefore describes disagreement within and around that group, not the whole field. Researchers who have published pessimistic analyses were not well represented live. The skeptic questions summarize what optimistic participants want skeptics to address; they are not answers, and the new response form is intended partly to correct this representation gap.

Areas of rough agreement

Six points of convergence within the May workshop cohort—not field-wide conclusions

Before mapping disagreements, it helps to note where the May workshop cohort broadly converged. Later independent responses challenge some of these points.

  • Humbird's amino-acid inputs should be updated. GFI's December 2025 analysis obtained bulk supplier quotes 2–10× below some inputs used by Humbird. This is evidence about ingredient prices, not validation of a complete medium or commercial process, and it was not challenged within the workshop cohort.
  • A transition from pharma-grade to food-grade inputs is achievable and likely. Bomkamp: "The switch to food-grade ingredients represents a very substantial 'low-hanging fruit' cost reduction opportunity — I would therefore expect that few products beyond the very earliest launched would use substantial amounts of pharma-grade inputs." Multiple respondents gave 100% probability (CM_17) to this before 2036.
  • The workshop cohort expected precision fermentation and plant molecular farming to reduce growth-factor costs. Fuchs gave each pathway 100% probability by 2036; Swartz agreed on direction while remaining more cautious about timing. A later anonymous independent response challenges whether these improvements close the full system-level cost gap.
  • Within the workshop cohort, the animal-welfare case was framed mainly as a timeline and probability question. Most participants expected CM to succeed at some scale. A later independent response questions whether animal cells can approach commodity-food economics at all, so this is not a field-wide consensus.
  • Density alone is a misleading performance metric. Cell volume per milliliter, performance-to-cost ratio (Frohlich/Swartz), and protein/lipid content (Swartz, McNulty) are more useful. There is not yet a shared standard metric for comparing bioprocess performance across scenarios.
  • Critical data gaps currently limit model validation. Swartz (S3 transcript): "There's basically no published studies that really quantify feed conversion ratio — what it actually is. There's also no information about inclusion rates... very little information around what is the actual cost of equipment."

Sources: public S1 and S3 transcripts and consent-checked beliefs submissions

Crux map

Five cruxes identified from public S1/S3 material, beliefs data, and public-cleared written submissions · no S2 discussion used

A crux is a specific empirical or technical question where: (a) different answers lead to meaningfully different 2036 cost projections; (b) reasonable, well-informed people currently disagree; and (c) the question is in principle resolvable by evidence. The five cruxes below are ordered roughly from most-upstream to most-downstream in the production process.

Crux 1

Cell line engineering: performance cascade, not just growth factor independence

Commercially validated growth, density, media needs, and growth-factor dependence

Cell line strategy is the most upstream cost-relevant decision in CM production. As Kubinyecz (S1) put it: "Immortalisation strategy determines proliferation rates, achievable density, growth factor dependence, and media requirements." Gene editing is one tool; the crux is not specifically whether gene editing succeeds, but what level of cell line performance — across all these dimensions — is commercially validated by 2030–2036.

Sub-crux 1a — GF independence via gene editing: Will autocrine-engineered cell lines (cells that produce their own growth factors) reach commercial-scale validation? Fuchs estimates 20% probability by 2036; Swartz similarly cautious. Most published TEAs do not model this pathway as a primary scenario. If it succeeds, the GF cost component collapses. If it doesn't, the field depends on external GF reduction pathways.
Sub-crux 1b — GF cost via non-gene-editing pathways: Precision fermentation and plant molecular farming as sources of cheap recombinant GFs. Fuchs: 100% probability by 2036. Swartz: directionally correct, timeline uncertain. Small molecule substitutes and thermostable variants are additional pathways discussed; both have remaining scientific uncertainty but are not ruled out.
Sub-crux 1c — Regulatory geography: The US does not provide a blanket FSMA "clearance" for gene-edited cultured-cell lines. FDA's pre-market consultation is product- and process-specific and examines cell lines and banks, manufacturing controls, and inputs; for chicken and other USDA-amenable species, oversight transfers at harvest to USDA-FSIS, which also requires inspection and label approval. One completed UPSIDE consultation did evaluate a bioengineered TERT-expressing chicken line, showing that such a line can pass a specific review—not that gene-edited lines are generally pre-cleared. Jurisdiction still affects timelines and economics, but the relevant unit is a defined product, process, and market-access pathway. See FDA's current overview and the FDA–USDA agreement.

Key sources: Kubinyecz S1 framing; Fuchs CM_12/CM_13 beliefs form; Swartz CM_12 written comment; S3 transcript (GF pathway discussion)

Crux 2

Media: hydrolysate substitution and the limits of media cost reduction

Food-grade inputs are one step; full-system hydrolysate economics are another

Two distinct steps in media cost reduction are often conflated. Workshop participants were broadly aligned on the first and actively divided on the second.

Step 1 (broad agreement): pharma-grade → food-grade inputs. Bomkamp describes this as "low-hanging fruit" that should happen as regulatory frameworks normalise. Multiple participants gave 100% probability to this transition before 2036 (CM_17 in beliefs form). This step reduces costs substantially but does not eliminate them.
Step 2 (active crux): replacing purified amino acids with hydrolysates. Hydrolysates — plant-derived or by-product protein digests — cost orders of magnitude less than purified AAs at commodity scale. Fuchs (ACIB/FEASTS) argues full or near-full substitution is achievable. Swartz and Bomkamp say partial substitution (~80%+) is plausible but full replacement faces unresolved quality-control barriers. Swartz's CM_12 comment: "Hydrolysates may become incorporated in a decent number of manufacturers' media formulations over the next decade. It is unlikely you'd fully replace purified AAs. You'd still likely need to supplement them in. It's also unclear if hydrolysates are truly cost beneficial."

The key unresolved question, as Swartz put it at the end of S1: "The biggest question for me is whether the hydrolysates can meet nutritional needs for high-density growth in suspension settings, and whether this is actually more economically efficient than using purified nutrients." The cost difference between a Humbird-type scenario (largely purified AAs) and a Fuchs-type scenario (near-full hydrolysate substitution) is substantial — but the specific disagreement between workshop participants is about whether full substitution is achievable and net cost-positive at commercial density, not about whether some substitution will happen.

Would be very interesting to know if feed/energy conversion is improved by small peptide uptake. That would be a strong justification for using hydrolysates that I don't see discussed much. — Elliot Swartz, S1 chat

Key sources: Fuchs S1 presentation; Swartz CM_12 written comment; Bomkamp CM_17; S1 chat log; S1 transcript discussion

Crux 3

Cell productivity: density, process mode, FCR, and the binding constraint

The interaction among output rate, media use, contamination risk, and capital

Even if media costs fall substantially, the remaining hard problems are cell productivity (density × growth rate × bioreactor occupancy) and capital costs. Swartz's pre-workshop submission: "Media costs will be quite low. Questions remain around productivity and capital costs."

Cell density: Optimistic TEAs model 20–50 g/L. More conservative analyses work from lower figures consistent with current practice. A 2× gap in density assumption propagates as 2× more media cost per kg output. Tarka Abraham (Ivy Farm, S1) is an industry practitioner working at commercial-scale densities — their perspective on achievable density in 20kL+ bioreactors was flagged as among the most grounded real-world data points.
Process mode — fed-batch vs. perfusion: Frohlich (S3): "The economics of continuous processes, and in this case perfusion, I think are pretty undeniable if you do the numbers." But CDMO infrastructure is largely fed-batch-based, and contamination risk at CM-scale perfusion (two orders of magnitude beyond biopharma) is real and not yet resolved.
Feed conversion ratio: No published studies quantify this directly for CM cell lines (Swartz, S3 transcript). This is a named data gap — not an area of disagreement, but an area of unknown that prevents model validation.
Performance-to-cost ratio: Frohlich and Swartz's November 2025 paper proposed this as a better organizing metric: how much biomass can a given capital investment produce? This is independent of media costs and captures the capital × productivity interaction that density alone misses.
There's basically no published studies that really quantify feed conversion ratio — what it actually is. There's also no information about inclusion rates — what inclusion rates are actually going to yield tasty products. There's also very little information around what is the actual cost of equipment. How much capital do you need to build a facility of a certain size? Is a scale-up or scale-out approach more prudent, given capital constraints? — Elliot Swartz, S3 transcript

Key sources: Swartz S3 transcript (data gaps); Frohlich S3 transcript (process mode, performance-to-cost ratio); Abraham S1 (density, bioreactor scale); S3 chat (density, metrics discussion)

Crux 4

The product target: what is the end-point, and how does it constrain cost?

The effective cultured-cell inclusion rate may matter more than pure biomass parity

This crux was not in the pre-workshop framing but emerged prominently in S3. It may be more fundamental than the cost cruxes above: if the product target is undefined or wrong, optimizing for biomass cost is optimizing the wrong thing.

The product-definition gap (McNulty, Frohlich): Most current CM R&D proceeds from a biomass-production perspective rather than reverse-engineering from a target food product. Frohlich (S3): "I haven't seen a good analysis of what would make a meat substitute that is perhaps a hybrid of using plant and mycoprotein along with animal cells. How many animal cells would you actually need in the product to give it that flavor?" McNulty (S3): "We don't understand specifically what are the product attributes that we need to have at the end point to have a viable product that's going to drive market adoption."
Inclusion rate as a cost lever: If a hybrid product (CM cells + plant protein or mycoprotein) at 5–25% inclusion can deliver sensory parity at a fraction of the cost of a 100% CM product, the cost-parity timeline changes substantially. Bomkamp (S3) cited a 2025 paper where 1.2% heat-treated cell extract produced a substantial sensory boost in a hybrid Gyoza product. Frohlich argues this direction is underexplored: "Can we make a hybrid product... and get a reasonable taste? And if an investor were able to see and taste something like that, I think the money would be forthcoming."
"Price parity" requires a target (Bomkamp): Price parity with a Michelin-starred beef product is a near-term possibility. Price parity with commodity ground beef is a long-term target. Framing CM cost progress as a single threshold misrepresents the actual market entry pathway, which Bomkamp describes as "more of a journey than a single destination."
You've got to start with the end in mind. A lot of the companies I've been consulting for, it's like, well, let's make this biomass slop and then figure out what to do with it. It should be the other way around: what are you trying to make, and therefore design the cell culture process to provide the ingredient that's of importance to the final product? — Bert Frohlich, S3 transcript

Key sources: Frohlich S3 transcript; McNulty S3 transcript; Bomkamp S3 transcript (inclusion rate, price parity framing)

Crux 5

Capital availability and industry survival: will the field reach dedicated-plant scale?

A path-to-commercialization question, distinct from conditional production cost

This crux is different in kind from Cruxes 1–4. Those concern what 2036 production costs will be if the industry reaches commercial scale. This one concerns whether it does. The workshop organizer noted in S3 that CDMO infrastructure is not the right focus for forecasting 2036 costs — "that's an intermediate testing ground" — but the capital question is real and unresolved.

The funding gap: Swartz (S3): "What the industry needs is money that is gonna yield steel in the ground, and that is the hardest thing to come by right now." GFI's GINA framework estimates $10 billion/year of public + private investment is needed for alternative proteins broadly. Current public funding is far below that. Private funding has contracted significantly since 2022.
The CDMO-to-dedicated-plant transition: CDMO runs and pilot facilities provide some current empirical information, while many TEAs model hypothetical at-scale dedicated facilities. Moving between those stages requires substantial, long-lived capital; the public evidence does not support one universal facility-cost figure. The financing timeline affects whether commercial-scale dedicated plants exist in meaningful quantity by 2036.
Regulatory survival risk: Italy's 2023 CM production ban directly affected Bruno Cell (Lattanzi). EU regulatory timelines are long. If early commercial scale is US-only or Singapore-only, the global trajectory is different from a scenario where EU and UK markets open by 2030.
Note on CM_01: Crux 5 does not directly change what it costs to produce CM biomass at a hypothetical 2036 dedicated facility — that's what CM_01 asks. But it does affect the probability distribution over whether any such facility exists. If the industry does not survive the funding drought, the "2036 cost" becomes academic. This is why Lattanzi's pessimistic cost estimate ($100/kg) does not translate to pessimism about the value of CM investment — he assigns high value to CM if it succeeds, and his risk assessment is primarily about timeline and capital, not ultimate technical feasibility.

Key sources: Swartz S3 transcript (capital, market shaping); Frohlich S3 transcript (government investment, GINA); Lattanzi beliefs form CM_02; public sector-funding reports

Key questions for skeptics

Six challenges from the more optimistic side; open one question at a time

In S3, David Reinstein asked: "What would we want to put forward to the skeptics? What would you want them to answer? What am I getting wrong here?" The questions below are challenges that optimistic participants think a well-informed skeptic should address—not claims that skepticism is mistaken.

Q1 · Media costs

GFI's December 2025 analysis found real bulk supplier quotes for key amino acids 2–10× below Humbird's projections. Given that, what is your revised estimate for basal media cost at food-grade, industrial scale in 2036 — and what specific input or assumption prevents it from falling further?

What would update this: detailed bulk supplier data by amino acid type; experimental evidence on whether hydrolysates meet nutritional needs at commercial suspension density.

Q2 · Cell line performance trajectory

CHO cells in biopharma went from ~1–2 million cells/mL (1980s) to 100+ million/mL under perfusion, over 40 years of focused optimization. CM-specific cell lines have had ~5–10 years. At what rate do you expect CM cell line performance to improve on the relevant metrics (density, FCR, GF independence), and why is that rate different from CHO's trajectory? What specific biological or engineering constraint creates the ceiling?

What would update this: published FCR data for CM cell lines; density benchmarks from companies willing to share (even non-attributed); results from open academic programs (NICA, ACIB, FEASTS).

Q3 · Growth factor cost pathways

Fuchs estimates 100% probability that precision fermentation and plant molecular farming will produce recombinant growth factors at cost-competitive prices by 2036. Swartz sees this as directionally correct. What is your probability estimate, and what specific technical or commercial obstacle prevents this from happening within a decade in at least one jurisdiction?

What would update this: demonstration at industrial fermentation scale; regulatory clearance for recombinant GF use in CM production in at least one major jurisdiction.

Q4 · Inclusion rates and hybrid products

If a hybrid CM product (animal cells + plant protein or mycoprotein) at 5–20% animal cell inclusion can deliver sensory parity with conventional meat in relevant market segments, the cost-parity threshold is 5–20× lower than if 100% animal cells are required. What is your estimate of the minimum effective inclusion rate for a commercially viable CM product, and on what evidence?

What would update this: published sensory studies with varied inclusion rates; investor willingness-to-fund data on hybrid products; regulatory clarity on labelling requirements for hybrid products.

Q5 · The learning-curve analogy

Solar PV and battery storage both saw 80–90% cost reductions over roughly a decade once manufacturing scaled up, driven by learning curves, R&D, and competitive pressure. Swartz suggests a similar trajectory is plausible for CM given enough capital investment. What makes CM's cost trajectory more like biopharma (costs plateau due to biological and regulatory constraints) than solar/batteries (steep learning curve with scale)? Is this a claim about biology, about regulation, or about market structure?

What would update this: evidence of learning-curve effects in early production runs; successful demonstration of cost reduction from pilot to pilot-scale within a single company.

Q6 · Regulatory and geographic scope

The US has a product-specific FDA consultation process, followed for amenable species by USDA-FSIS inspection and label approval; it has not broadly pre-cleared gene-edited cell lines. If early commercial scale is confined to the US and/or Singapore for 2026–2032, what does the cost trajectory look like, and does that change your 2036 estimate for the global cost frontier?

What would update this: completed consultations and inspection grants for defined products and processes; demonstrated commercial production at scale; decisions in additional jurisdictions; and published regulator guidance specific to engineered cultured-animal cells.

Developed from public S3 discussion about what would change a skeptic's mind

Key questions for optimists

Three top-down stress tests from an anonymized independent argument

This is a symmetric stress test, not an endorsement of the anonymous respondent's $500/kg median. Their distinctive claim is that a top-down benchmark can reveal system-level constraints that optimistic bottom-up models miss.

O1 · Benchmark against mature fermentation

Estimate cultured-meat production cost top-down against yeast biomass production. What volumetric productivity (g/L/day), doubling time, reactor occupancy, and contamination loss do you assume for cultured animal cells in 2036, and how do those quantities compare with an industrial yeast process?

What would update this: a harmonized public comparison on the same output, facility, utilization, and cost basis; measured large-reactor productivity and loss rates.

O2 · Explain the economic floor

If mature yeast-derived single-cell protein remains in roughly the same price order as meat, what mechanism lets slower, more fragile animal cells—with more complex inputs and controls—reach or undercut the relevant meat benchmark? Which differences in product value or inclusion rate are doing the work?

What would update this: verified full-economic-cost data from commercial CM output; evidence separating biomass cost from product premium and hybrid inclusion effects.

O3 · Identify the fragile assumption

In your preferred bottom-up TEA, which single assumption would break the headline result if it were wrong by one order of magnitude? Which interactions among media use, growth, density, downtime, and capital could make several individually plausible assumptions fail jointly?

What would update this: structural sensitivity across independently built models, not only one-at-a-time parameter changes inside one model.

Added July 20, 2026 from a public-cleared anonymized argument; biographical and timing details withheld

Implications for the cost model

Five concrete modeling changes implied by the crux map

The map suggests several places where the interactive cost model dashboard needs development or explicit scenario treatment:

Cell line scenario branching: The model should represent distinct scenarios—with and without optimized, potentially gene-edited lines achieving high density and growth-factor independence—and quantify the gap rather than assuming in advance that it dominates every other parameter.
Hydrolysate substitution as a slider, not a binary: Rather than assuming full hydrolysate substitution (Fuchs) or minimal substitution (Humbird), the model should parameterize substitution rate (0–100%) alongside a QC cost factor that increases with substitution rate. This makes the Swartz/Fuchs crux explicit in the model output (Crux 2).
FCR as a named unknown: The model currently does not represent feed conversion ratio explicitly. Given Swartz's statement that no published data quantifies this, it should be represented as a wide prior rather than a fixed assumption, with sensitivity analysis showing how cost changes as FCR varies (Crux 3).
Inclusion rate as a separate cost lever: Bomkamp's work on translating biomass cost to product cost via inclusion rate is not currently in the model. A simple inclusion-rate slider (1%–100%) showing final product cost would make Crux 4 legible to model users and funders.
Capital availability is a path variable, not a cost parameter: The CDMO-to-dedicated-plant transition and the capital availability question (Crux 5) cannot be represented as a cost input to the 2036 model — they affect the probability that the 2036 scenario occurs at all. This distinction should be explicit in how the model is presented.

Respond to the crux map

A useful response can be short. Tell us where you disagree, what evidence bears on it, and what would change your view. We are particularly interested in technically grounded skeptical responses and in clear answers from optimists to the top-down challenges.

Short argument hereUse this form for one crux or question. We may incorporate public responses into a dated revision of the map.
Numerical belief distributionUse the beliefs form if you can provide p10, median, and p90 estimates. That keeps the quantitative synthesis comparable.
Line-level public commentUse the Hypothes.is sidebar if your response concerns one sentence or source and you want a public discussion thread.

Describe the basis of your view without identifying yourself if you prefer anonymity.
Only for clarification or follow-up. It will not appear in public output.
How may we use this response?